Melanoma does not become steadily more dangerous as people age. New research from the United States shows that cancer spread peaks in middle age and then drops again in extreme old age, a pattern that contradicts long held assumptions.
Scientists at Fox Chase Cancer Center in Philadelphia presented the findings at the American Association for Cancer Research annual meeting. The study used mice of different ages to track how melanoma behaved over time.
Cancer Spread Surged in Middle Aged Mice, Then Fell in Old Age
Researchers measured melanoma spread in three groups of mice: young, middle aged, and very old. The results surprised them. Young mice had the lowest levels of cancer spread. Middle aged mice showed the highest levels. Very old mice saw spread drop again, nearly to the levels seen in the young group.
This pattern suggests that the relationship between age and cancer is not a straight line. The immune system appears to change in ways that affect how aggressively cancer can move through the body.
A Special Immune Cell May Explain the Pattern
The team focused on a type of immune cell called gamma delta T cells. These cells act as an early defense system, helping keep cancer dormant and preventing it from spreading to organs like the lungs and liver.
Young mice and very old mice had high levels of these protective cells. Their tumors were more likely to stay dormant or spread slowly. Middle aged mice had fewer gamma delta T cells, and melanoma spread much more aggressively.
The researchers also found that melanoma cells themselves can weaken the immune system as animals age. In middle aged mice, the cancer released molecules that suppressed or exhausted gamma delta T cells. Once those defenses weakened, previously dormant cancer cells became active and spread.
Additional experiments confirmed the importance of these cells. When researchers removed gamma delta T cells from young and very old mice, melanoma spread increased significantly. When they blocked the signals that suppress immune activity in middle aged mice, protection was restored and spread decreased.
Why Most Cancer Studies Miss This
Fewer than 10% of mouse cancer experiments use aged animals. Most rely on mice that correspond to humans in their early 20s. That gap may help explain why many cancer therapies that work well in the lab fail in human trials.
Lead investigator Mitchell Fane, a cancer biologist specializing in aging, noted that it is easy to personalize care for young, fit patients who may not experience as many toxicities. Understanding how therapies affect older patients would give doctors more and better treatment options.
The study focused on melanoma, but the findings raise questions about whether other cancers follow similar age related patterns. The results suggest that the immune system's ability to control cancer may not simply decline with age. It may rise, fall, and rise again.
